Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease
Clofazimine Inhalation Suspension demonstrated effective antimicrobial lung concentrations and achievable long-term coverage with potential for less systemic toxicity than oral clofazimine. This novel formulation is an alternative delivery strategy to oral ingestion for pulmonary NTM disease. Further evaluation in the phase 3 ICoN-1 global clinical trial is underway.
Authors
- Burkhard Blank
- Thomas Hofmann (ORCID: https://orcid.org/0000-0002-1389-6374)
- Wassim H. Fares (ORCID: https://orcid.org/0000-0001-9462-8103)
- Michael Castagna
Institutions
- Western Connecticut State University (US)
- Danbury Hospital (US)
Publication Details
- Journal
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1177/19412711251370275
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00